Ameriprise
BLTE

Ameriprise’s Belite Bio BLTE Stock Holding History

Ameriprise’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$466K Buy
3,029
+262
+9% +$40.2K ﹤0.01% 3682
2026
Q1 		$441K Sell
2,767
-10,454
-79% -$1.76M ﹤0.01% 3635
2025
Q4 		$2.11M Buy
13,221
+10,190
+336% +$1.21M ﹤0.01% 2970
2025
Q3 		$224K Buy
+3,031
New +$199K ﹤0.01% 3879
2025
Q2 		– Sell
-3,075
Closed -$204K – 3982
2025
Q1 		$204K Buy
+3,075
New +$185K ﹤0.01% 3792

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise's BLTE Position: Q2 2026 in Review

Ameriprise increased its Belite Bio (BLTE) stake by 9.5% in Q2 2026, buying an estimated $40.2K and bringing the position to 3,029 shares worth $466K. The position accounts for ﹤0.01% of the portfolio, ranked #3682.

Ameriprise first reported a position in BLTE in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.11M in Q4 2025. 80 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Ameriprise held 3,029 shares of Belite Bio worth $466K as of Q2 2026.
  • Ameriprise bought 262 Belite Bio shares in Q2 2026, an estimated $40.2K.
  • Belite Bio made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3682 holding.
  • Ameriprise first reported a position in Belite Bio in Q1 2025 and has held it in 5 quarters since.
  • Ameriprise's Belite Bio position peaked at $2.11M in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.